Start your Trading & Investing Journey with us

Avience Biomedicals Limited is a healthcare diagnostics and medical devices company engaged in manufacturing, distribution and servicing of in-vitro diagnostic (IVD) products, molecular diagnostic solutions, laboratory consumables and medical equipment. The company generates revenue through manufacturing diagnostic kits, culture media, biochemistry reagents, laboratory plasticware, electrolyte analysers and related healthcare consumables under the "Avienbio" brand, while also distributing imported diagnostic equipment from global partners.

Customers, End Markets & Manufacturing Facilities

The company serves pathology laboratories, hospitals, diagnostic centres, healthcare institutions, research organizations and medical testing facilities across India. Its manufacturing operations are supported by facilities focused on diagnostic kits, laboratory consumables and medical devices. The proposed new manufacturing facility at the Medical Device Park under YEIDA in Uttar Pradesh is expected to strengthen production capabilities, improve operational efficiencies and support future product diversification.

Product Portfolio & Value Chain Positioning

Avience Biomedicals operates across multiple segments of the diagnostics value chain. Its portfolio includes rapid diagnostic test kits, molecular diagnostic products, viral transport media, HIV, HBsAg, malaria and dengue test kits, serology products, biochemistry analysers, biochemistry reagents, culture media, laboratory consumables and diagnostic equipment. The company combines manufacturing, distribution and after-sales service capabilities, allowing it to participate across both consumables and equipment-based healthcare diagnostics markets.

Expansion Plans, Capex & Corporate Actions

The IPO proceeds are primarily earmarked for establishing a new manufacturing facility at Industrial Plot No. 70, Sector-28, Medical Device Park, YEIDA, Gautam Buddha Nagar, Uttar Pradesh. Additional funds will be utilized for working capital requirements and general corporate purposes. The expansion is expected to increase manufacturing capabilities, support import substitution opportunities and strengthen the company's presence within India's growing diagnostics and medical devices industry.

Employees & Banking Partners

The company is led by promoters Dharam Deo Choudhary, Ram Nagina Choudhary, Janardan Pal and Deepa Choudhary, supported by an experienced management team and trained workforce focused on diagnostics manufacturing and healthcare distribution.

End-Section Note:
Detailed employee count, customer concentration by segment, manufacturing capacity utilization, order book position, execution status and banking relationship details were not disclosed in the reviewed public sources.

Management & Strategic Vision

Management's strategy is focused on building Avience Biomedicals into an integrated diagnostics and medical devices platform with stronger in-house manufacturing capabilities. The company has evolved from supplying essential diagnostic products such as VTM, COVID, HIV, malaria and dengue kits into a broader diagnostics solutions provider serving laboratories and healthcare institutions. Management is also investing in new product approvals and manufacturing licenses to expand its portfolio.

The proposed manufacturing facility at the YEIDA Medical Device Park represents a key strategic initiative aimed at increasing manufacturing scale, improving margins through higher in-house production and reducing reliance on outsourced procurement. Growth funding is expected to come through a combination of IPO proceeds, internal accruals and working capital facilities. The company also appears focused on export expansion and deeper penetration into India's diagnostics market.

End-Section Note:
Formal management guidance, long-term revenue targets, EBITDA objectives and quantified capacity expansion metrics beyond disclosed capex plans were not available in the reviewed sources.

Industry Analysis

Avience Biomedicals operates within India's rapidly growing diagnostics, IVD and medical devices industry. The sector benefits from increasing healthcare expenditure, rising disease awareness, expanding diagnostic testing volumes, growing health insurance penetration and government initiatives promoting domestic manufacturing under the Make in India program. The company has been recognized under the Make in India initiative and participates in segments including diagnostic kits, medical devices and laboratory consumables.

India's diagnostics market continues to benefit from structural healthcare trends including preventive healthcare adoption, rising chronic disease prevalence, expansion of diagnostic laboratory networks and increasing demand for affordable testing solutions. Molecular diagnostics and point-of-care testing represent some of the fastest-growing segments due to technological advancements and improved accessibility.

The competitive landscape includes multinational diagnostics companies, domestic IVD manufacturers, laboratory consumable producers and medical device suppliers. Industry leaders typically compete based on product quality, regulatory approvals, manufacturing capabilities, distribution reach and technological innovation. Avience's combination of manufacturing, distribution and diagnostic equipment partnerships provides diversified exposure across the healthcare diagnostics ecosystem.

End-Section Note:
Specific domestic and global market-size figures, industry CAGR estimates and detailed market-share data were not disclosed in the reviewed sources.

Key Risk Factors

1. Regulatory Compliance Risk

The diagnostics and medical devices industry operates under stringent regulatory frameworks. Any failure to comply with manufacturing, product quality or healthcare regulations could result in penalties, product recalls or business disruptions.

2. Customer Concentration Risk

A significant proportion of revenue is generated from a limited group of customers. Dependence on major customers could expose the company to revenue volatility if customer relationships weaken or procurement patterns change.

3. Supplier Dependency

The company relies on a concentrated supplier base for procurement. Supply disruptions, pricing pressures or vendor-related operational challenges could negatively affect production schedules and profitability.

4. Working Capital Intensity

The business operates with relatively high receivable and inventory cycles. Extended collections or inventory build-up may increase funding requirements and place pressure on operating cash flows.

5. Expansion Execution Risk

The success of the proposed YEIDA manufacturing facility will depend on timely project execution, capacity utilization and market demand. Delays or cost overruns could affect expected returns from expansion investments.

6. Competitive Market Dynamics

The diagnostics and medical devices market remains highly competitive with participation from global and domestic players. Pricing pressure, technological disruption or superior product offerings by competitors may impact market share.

7. Dependence on Healthcare Spending

Demand for diagnostic products is influenced by healthcare spending trends, public health programs and diagnostic testing volumes. Any slowdown in healthcare investments may affect growth prospects.

End-Section Note: Detailed litigation risks, contingent liabilities and product-specific regulatory exposures were not available in the reviewed sources.

Strengths & Opportunities

1. Diversified Diagnostics Portfolio

The company offers a broad range of diagnostic kits, molecular diagnostics, serology products, reagents, laboratory consumables and diagnostic equipment, reducing dependence on any single product category.

2. Integrated Business Model

Avience combines manufacturing, distribution and equipment servicing capabilities, enabling participation across multiple layers of the healthcare diagnostics value chain and creating diversified revenue streams.

3. Strong Financial Growth

Revenue increased from ₹24.37 crore in FY24 to ₹45.97 crore in FY25, while profit after tax rose from ₹2.14 crore to ₹7.23 crore. EBITDA margins also expanded significantly, indicating improving operating leverage.

4. Manufacturing Expansion Opportunity

The planned facility at the YEIDA Medical Device Park can significantly enhance production capacity, support localization initiatives and strengthen long-term profitability through higher in-house manufacturing.

5. Exposure to High-Growth Healthcare Segments

The company operates in molecular diagnostics, IVD products and medical devices—segments benefiting from increasing healthcare awareness, diagnostic testing demand and technological advancement.

6. Favorable Industry Tailwinds

Government support for domestic medical device manufacturing, increasing healthcare expenditure, import substitution opportunities and expanding diagnostics infrastructure create long-term growth opportunities for the company.